Content deleted Content added
No edit summary |
Add Infobox 'technology standard' |
||
Line 1:
{{Infobox technology standard
| title = BioCompute Object
| long_name =
| image =
| caption =
| status = [https://saaem-stg.ieee.org/project/2791.htm Active IEEE Working Group]
| year_started = <!-- {{Start date|2014|07|10|df=y}} -->
| first_published = <!-- {{Start date|YYYY|MM|DD|df=y}} -->
| version = <!-- 1.0 -->
| version_date = <!-- {{Start date|2016|07|08|df=y}} -->
| preview =
| preview_date =
| organization =
| committee =
| editors =
| authors =
| base_standards =
| related_standards = [[Common_Workflow_Language|Common Workflow Language]]
| abbreviation = BCO
| ___domain =
| license = [[BSD_licenses#3-clause_license_("BSD_License_2.0",_"Revised_BSD_License",_"New_BSD_License",_or_"Modified_BSD_License")|BSD-3-clause]]
| website = {{URL|https://osf.io/h59uh/}}
}}
The '''BioCompute Object (BCO) Project''' is a community-driven initiative to build a framework for standardizing and sharing computations and analyses generated from [[High-throughput sequencing]] (HTS), also referred to as [[next-generation sequencing]] (NGS) or [[massively parallel sequencing]] (MPS).<ref>Simonyan V, Goecks J, Mazumder R. Biocompute Objects—A Step towards Evaluation and Validation of Biomedical Scientific Computations. PDA journal of pharmaceutical science and technology. 2017;71(2):136-146. doi:10.5731/pdajpst.2016.006734.</ref> Originally started as a collaborative contract between the [[George Washington University]] and the [[Food and Drug Administration]], the project has grown to include over 20 universities, biotechnology companies, public-private partnerships and pharmaceutical companies including Seven Bridges and [[Harvard Medical School]].<ref>{{Cite web|url=https://www.europeanpharmaceuticalreview.com/news/67524/biocompute-genomic-data/|title=BioCompute Objects specifications to advance genomic data analysis|website=www.europeanpharmaceuticalreview.com|language=en|access-date=2017-12-21}}</ref> The BCO aims to ease the exchange of HTS workflows between various organizations, such as the FDA, pharmaceutical companies, contract research organizations, bioinformatic platform providers, and academic researchers.
| |||